This study examined the current changes of human ether-a-go-go-related gene (hERG) mutation derived from a LQT2 Chinese family with a highly penetrating phenotype. Mutation was identified and site-directed mutagenesis was performed to induce the mutation in wild-type (WT) hERG. WT hERG and mutated V535M were cloned and transiently expressed in HEK293 cells. At the 48th and 72nd h after transfection, membrane currents were recorded using whole cell patch-clamp procedures. An A>G transition at 1605 resulting in replacement of V535M was identified. Compared to WT, V535M mutation significantly decreased tail currents of hERG. At test potential of -40 mV after depolarizing at +50 mV, tail current densities were 83.35±7.06 pA/pF in WT and 50.38±7.74 pA/pF in V535M respectively (n=20, P<0.01). Gating kinetics of hERG revealed that V (1/2) of steady-state inactivation shifted to negative potential in the mutant (V (1/2,V535M): -61.81±1.7 mV vs. V (1/2, WT): -43.1±0.71 mV). The time constant of recovery from inactivation was markedly prolonged in the mutant compared to WT among test potentials. V535M hERG mutation demonstrated markedly decreased tail current densities, which suggests that V535M is a new loss-of-function mutation of hERG channel responsible for LQT2.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11596-011-0670-2DOI Listing

Publication Analysis

Top Keywords

herg mutation
8
v535m
5
herg
5
mutation
5
electrophysiological study
4
study v535m
4
v535m herg
4
mutation lqt2
4
lqt2 study
4
study examined
4

Similar Publications

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.

Cell Mol Life Sci

November 2024

School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.

Article Synopsis
  • Potassium channels from the human hERG gene are affected by various drugs, and this study specifically investigates the effects of chiral disopyramide, a Class Ia antiarrhythmic, on hERG currents in HEK 293 cells.* -
  • The findings show that the S(+) enantiomer of disopyramide is more potent at inhibiting hERG current compared to the R(-) form, with IC values of 3.9 µM and 12.9 µM respectively, and certain mutations in hERG alter these effects.* -
  • Molecular simulations indicate that the S(+) form binds more effectively to specific residues in the hERG channel, while the R(-)
View Article and Find Full Text PDF

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated K1.1 Channel.

J Med Chem

November 2024

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Gain-of-function (GOF) mutations of the sodium-activated potassium channel K1.1 (Slack, Slo2.2, or K4.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiovascular diseases, particularly hereditary Long QT Syndrome (LQTS), are linked to ion channel dysfunctions, leading to a higher risk of sudden cardiac death, especially with the LQT2 type caused by mutations in the hERG gene.
  • Specific high-affinity hERG blockers like E-4031 could potentially rescue these dysfunctional channels, but the mechanisms behind their effectiveness are unclear.
  • The study employs accelerated molecular dynamics simulations to show how mutations in the hERG channel alter its structure and trafficking, and suggests that E-4031 may inhibit these detrimental changes, paving the way for new treatments targeting the underlying cellular issues.
View Article and Find Full Text PDF

The human ether-a-go-go-related gene (hERG) encodes the Kv11.1 (or hERG) channel that conducts the rapidly activating delayed rectifier potassium current (I). Naturally occurring mutations in hERG impair the channel function and cause long QT syndrome type 2.

View Article and Find Full Text PDF

Gain-of-function mutations in the gene, which encodes the sodium-activated potassium channel known as SLACK, are associated with the rare but devastating developmental and epileptic encephalopathy known as epilepsy of infancy with migrating focal seizures (EIMFS). The design of small molecule inhibitors of SLACK channels represents a potential therapeutic approach to the treatment of EIMFS, other childhood epilepsies, and developmental disorders. Herein, we describe a hit optimization effort centered on a xanthine SLACK inhibitor () discovered via a high-throughput screen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!